Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
8398300
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Disposal of Treasury Shares Through a Third-Party Allotment
Who receives how much8,398,300Shares
普通株式 8,398,300 株（自己株式）
The Master Trust Bank of Japan, Ltd. (ESOP Trust Account for Share Grants)8,398,300株
The lower thin line represents the existing number of shares to which these shares will be added.
1株につき2,435.5円
Total issue value20,454,059,650Yen
発行済株式総数
発行済株式総数に対し1.68％、総議決権個数に対し1.79％
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Categories and Number of Persons Covered
米国子会社Deciphera Pharmaceuticals, Inc.の従業員（人数・区分別割当株数はNot disclosed）
Intended allottee's holding policy
株式交付規程に従い、一定の要件を充足した本従業員に交付する。信託期間中に一時に株式市場に流出することは想定されていない。
Payment date
25 March 2026
Basis for determining the amount to be paid
2026年3月4日の東京証券取引所における当社株式の終値2,435.5円。ディスカウント・プレミアムなし。
Procedures under the Corporate Code of Conduct
希薄化率は25％未満で支配株主の異動もないため、独立第三者からの意見入手および株主の意思確認手続は不要。監査役全員4名（うち社外監査役2名）が処分価額の算定根拠は合理的で、特に有利な処分価額ではない旨の意見を表明。
Impact on Business Performance
The impact on the stock market is expected to be minor.
| Item | Details |
|---|---|
| Type of issuance or disposal | Disposal of Treasury Shares Through a Third-Party Allotment |
| Number of shares to be issued or disposed of | 普通株式 8,398,300 株（自己株式） |
| Issue price and disposal price | 1株につき2,435.5円 |
| Total issue value | 20,454,059,650円 |
| Payment date | 25 March 2026 |
| Intended allottee | Name The Master Trust Bank of Japan, Ltd. (ESOP Trust Account for Share Grants) / Number of Shares 8,398,300株 |
| Intended allottee's holding policy | 株式交付規程に従い、一定の要件を充足した本従業員に交付する。信託期間中に一時に株式市場に流出することは想定されていない。 |
| Dilution Rate | 発行済株式総数に対し1.68％、総議決権個数に対し1.79％ |
| Total number of issued shares | 498,692,800株 → 498,692,800株（0％） |
| Basis for determining the amount to be paid | 2026年3月4日の東京証券取引所における当社株式の終値2,435.5円。ディスカウント・プレミアムなし。 |
| Categories and Number of Persons Covered | 米国子会社Deciphera Pharmaceuticals, Inc.の従業員（人数・区分別割当株数はNot disclosed） |
| Procedures under the Corporate Code of Conduct | 希薄化率は25％未満で支配株主の異動もないため、独立第三者からの意見入手および株主の意思確認手続は不要。監査役全員4名（うち社外監査役2名）が処分価額の算定根拠は合理的で、特に有利な処分価額ではない旨の意見を表明。 |
| Impact on Business Performance | The impact on the stock market is expected to be minor. |
Items this document does not state (15)
Amount of funds to be raisedEstimated issuance expensesSpecific use of fundsExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMost recent equity financingMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.米国子会社Deciphera社の従業員に対する長期インセンティブ株式報酬制度「株式付与ESOP信託」の導入に伴い、共同受託者である日本マスタートラスト信託銀行株式会社（株式付与ESOP信託口）に自己株式を処分するため。割り当てられた株式は一定の要件を満たした従業員に交付され、一時に株式市場へ流出することは想定されていないため、株式市場への影響は軽微で、処分株式数および希薄化の規模は合理的と判断している。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.